BioRestorative Therapies, Inc.
BRTX
$1.71
$0.021.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 124.35% | 660.91% | 38.14% | 11.82% | 421.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 124.35% | 660.91% | 38.14% | 11.82% | 421.62% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 107.25% | 601.63% | 28.06% | 11.82% | 421.62% |
| SG&A Expenses | -50.14% | -49.15% | -44.73% | -32.60% | -46.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.64% | -19.60% | -19.59% | -28.67% | -30.85% |
| Operating Income | 16.47% | 26.33% | 20.79% | 28.89% | 31.21% |
| Income Before Tax | 28.99% | -122.89% | 29.44% | 69.00% | -349.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.99% | -122.89% | 29.44% | 69.00% | -349.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.99% | -122.89% | 29.44% | 69.00% | -349.11% |
| EBIT | 16.47% | 26.33% | 20.79% | 28.89% | 31.21% |
| EBITDA | 16.94% | 26.89% | 21.27% | 29.15% | 31.66% |
| EPS Basic | 59.02% | -112.88% | 66.24% | 82.73% | -294.65% |
| Normalized Basic EPS | 101.89% | -112.88% | 66.24% | 82.73% | -294.68% |
| EPS Diluted | 58.90% | -134.46% | 65.99% | 82.73% | -294.65% |
| Normalized Diluted EPS | 101.89% | -134.74% | 66.24% | 82.73% | -294.68% |
| Average Basic Shares Outstanding | 73.34% | 77.68% | 108.98% | 79.46% | 27.99% |
| Average Diluted Shares Outstanding | 73.34% | -34.10% | 108.98% | 79.46% | 27.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |